Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by StockNews.com

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note released on Tuesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

Shares of BCLI opened at $1.21 on Tuesday. Brainstorm Cell Therapeutics has a 1 year low of $0.72 and a 1 year high of $10.05. The stock has a 50 day simple moving average of $1.21 and a two-hundred day simple moving average of $1.59. The firm has a market cap of $7.89 million, a P/E ratio of -0.25 and a beta of 0.35.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.